These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 30941100)

  • 21. Mild pituitary phenotype in 3- and 12-month-old Aip-deficient male mice.
    Lecoq AL; Zizzari P; Hage M; Decourtye L; Adam C; Viengchareun S; Veldhuis JD; Geoffroy V; Lombès M; Tolle V; Guillou A; Karhu A; Kappeler L; Chanson P; Kamenický P
    J Endocrinol; 2016 Oct; 231(1):59-69. PubMed ID: 27621108
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications.
    Jaffrain-Rea ML; Angelini M; Gargano D; Tichomirowa MA; Daly AF; Vanbellinghen JF; D'Innocenzo E; Barlier A; Giangaspero F; Esposito V; Ventura L; Arcella A; Theodoropoulou M; Naves LA; Fajardo C; Zacharieva S; Rohmer V; Brue T; Gulino A; Cantore G; Alesse E; Beckers A
    Endocr Relat Cancer; 2009 Sep; 16(3):1029-43. PubMed ID: 19556287
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclic nucleotide phosphodiesterases (PDEs) in human osteoblastic cells; the effect of PDE inhibition on cAMP accumulation.
    Ahlström M; Pekkinen M; Huttunen M; Lamberg-Allardt C
    Cell Mol Biol Lett; 2005; 10(2):305-19. PubMed ID: 16010295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins.
    Butt E; Beltman J; Becker DE; Jensen GS; Rybalkin SD; Jastorff B; Beavo JA
    Mol Pharmacol; 1995 Feb; 47(2):340-7. PubMed ID: 7870042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Induction of specific phosphodiesterase isoforms by constitutive activation of the cAMP pathway in autonomous thyroid adenomas.
    Persani L; Lania A; Alberti L; Romoli R; Mantovani G; Filetti S; Spada A; Conti M
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2872-8. PubMed ID: 10946896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. cAMP-specific phosphodiesterase inhibitors: promising drugs for inflammatory and neurological diseases.
    Martinez A; Gil C
    Expert Opin Ther Pat; 2014 Dec; 24(12):1311-21. PubMed ID: 25284693
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Do the aryl hydrocarbon receptor interacting protein variants (Q228K and Q307R) play a role in patients with familial and sporadic hormone-secreting pituitary adenomas?
    Yarman S; Ogret YD; Oguz FS
    Genet Test Mol Biomarkers; 2015 Jul; 19(7):394-8. PubMed ID: 25938168
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Aryl hydrocarbon receptor interacting protein (AIP) gene mutation analysis in children and adolescents with sporadic pituitary adenomas.
    Georgitsi M; De Menis E; Cannavò S; Mäkinen MJ; Tuppurainen K; Pauletto P; Curtò L; Weil RJ; Paschke R; Zielinski G; Wasik A; Lubinski J; Vahteristo P; Karhu A; Aaltonen LA
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):621-7. PubMed ID: 18410548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activated AMP-protein kinase (pAMPK) is overexpressed in human somatotroph pituitary adenomas.
    Bizzi MF; Drummond JB; Pinheiro SVB; Paulino E; Araújo SA; Soares BS; Giannetti AV; Schweizer JROL; Barry S; Korbonits M; Ribeiro-Oliveira A
    Mol Cell Endocrinol; 2024 Oct; 592():112318. PubMed ID: 38908427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro.
    Trivellin G; Butz H; Delhove J; Igreja S; Chahal HS; Zivkovic V; McKay T; Patócs A; Grossman AB; Korbonits M
    Am J Physiol Endocrinol Metab; 2012 Sep; 303(6):E708-19. PubMed ID: 22811466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Somatotroph-Specific
    Gillam MP; Ku CR; Lee YJ; Kim J; Kim SH; Lee SJ; Hwang B; Koo J; Kineman RD; Kiyokawa H; Lee EJ
    J Endocr Soc; 2017 Feb; 1(2):78-95. PubMed ID: 29264469
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Very low frequency of germline GPR101 genetic variation and no biallelic defects with AIP in a large cohort of patients with sporadic pituitary adenomas.
    Lecoq AL; Bouligand J; Hage M; Cazabat L; Salenave S; Linglart A; Young J; Guiochon-Mantel A; Chanson P; Kamenický P
    Eur J Endocrinol; 2016 Apr; 174(4):523-30. PubMed ID: 26792934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Somatostatin analogues increase AIP expression in somatotropinomas, irrespective of Gsp mutations.
    Jaffrain-Rea ML; Rotondi S; Turchi A; Occhi G; Barlier A; Peverelli E; Rostomyan L; Defilles C; Angelini M; Oliva MA; Ceccato F; Maiorani O; Daly AF; Esposito V; Buttarelli F; Figarella-Branger D; Giangaspero F; Spada A; Scaroni C; Alesse E; Beckers A
    Endocr Relat Cancer; 2013 Oct; 20(5):753-66. PubMed ID: 23940012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Aip regulates cAMP signalling and GH secretion in GH3 cells.
    Formosa R; Xuereb-Anastasi A; Vassallo J
    Endocr Relat Cancer; 2013 Aug; 20(4):495-505. PubMed ID: 23702468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [AIP mutations in familial and sporadic pituitary adenomas: local experience and review of the literature].
    Fajardo-Montañana C; Daly AF; Riesgo-Suárez P; Gómez-Vela J; Tichomirowa MA; Camara-Gómez R; Beckers A
    Endocrinol Nutr; 2009; 56(7):369-77. PubMed ID: 19883897
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distribution and function of 3',5'-Cyclic-AMP phosphodiesterases in the human ovary.
    Petersen TS; Kristensen SG; Jeppesen JV; Grøndahl ML; Wissing ML; Macklon KT; Andersen CY
    Mol Cell Endocrinol; 2015 Mar; 403():10-20. PubMed ID: 25578602
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues.
    Oriola J; Lucas T; Halperin I; Mora M; Perales MJ; Alvarez-Escolá C; Paz de MN; Díaz Soto G; Salinas I; Julián MT; Olaizola I; Bernabeu I; Marazuela M; Puig-Domingo M
    Eur J Endocrinol; 2013 Jan; 168(1):9-13. PubMed ID: 23038625
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aryl hydrocarbon receptor interacting protein gene (AIP) mutations are rare in patients with hormone secreting or non-secreting pituitary adenomas.
    Buchbinder S; Bierhaus A; Zorn M; Nawroth PP; Humpert P; Schilling T
    Exp Clin Endocrinol Diabetes; 2008 Nov; 116(10):625-8. PubMed ID: 18484068
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hyperplasia-adenoma sequence in pituitary tumorigenesis related to aryl hydrocarbon receptor interacting protein gene mutation.
    Villa C; Lagonigro MS; Magri F; Koziak M; Jaffrain-Rea ML; Brauner R; Bouligand J; Junier MP; Di Rocco F; Sainte-Rose C; Beckers A; Roux FX; Daly AF; Chiovato L
    Endocr Relat Cancer; 2011 Jun; 18(3):347-56. PubMed ID: 21450940
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Aryl hydrocarbon receptor interacting protein (AIP) mutations occur rarely in sporadic parathyroid adenomas.
    Pardi E; Marcocci C; Borsari S; Saponaro F; Torregrossa L; Tancredi M; Raspini B; Basolo F; Cetani F
    J Clin Endocrinol Metab; 2013 Jul; 98(7):2800-10. PubMed ID: 23633209
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.